Tyra Biosciences, Inc. (TYRA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, President, CEO, Secretary, Treasurer & Director | 1.07M | -- | 1979 |
| Mr. Daniel Bensen | Co-Founder & COO | 737.64k | -- | 1975 |
| Dr. Douglas Warner M.D. | Chief Medical Officer | 627.9k | -- | 1972 |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer | -- | -- | 1955 |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer | 536.19k | -- | 1963 |
| Mr. Ali D. Fawaz J.D. | General Counsel | 629.23k | -- | -- |
| Ms. Sarah Honig | Senior VP of Corporate Development & Strategy | -- | -- | -- |
| Liz Pagano | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Piyush R. Patel Ph.D. | Chief Development Officer | -- | -- | 1965 |
| Mr. Erik Goluboff | Senior Vice President of Clinical Development | -- | -- | -- |
Tyra Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 60
Description
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Corporate Governance
Upcoming Events
August 5, 2025 at 8:00 PM UTC - August 11, 2025 at 8:00 PM UTC
Tyra Biosciences, Inc. Earnings Date